Loading clinical trials...
Loading clinical trials...
A Prospective Study of Radiofrequency Ablation Combined With Systematic Neoadjuvant Therapy in the Treatment of Recurrent Hepatocellular Carcinoma
Conditions
Interventions
Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab
RFA
Locations
1
China
Institute of hepatobiliary surgery,Southwest Hospital
Chongqing, Chongqing Municipality, China
Start Date
November 1, 2021
Primary Completion Date
November 1, 2022
Completion Date
October 30, 2023
Last Updated
March 14, 2022
NCT07118202
NCT05990959
NCT02423343
NCT01009593
Lead Sponsor
Southwest Hospital, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions